Xbiotech results from randomized double-blinded phase 1/2 study suggest potential breakthrough treatment for advanced pancreatic cancer

Findings show trends for reduced toxicities and better outcomes for subjects receiving onivyde/5-fu combination and targeted anti-il-1alpha therapy findings show trends for reduced toxicities and better outcomes for subjects receiving onivyde/5-fu combination and targeted anti-il-1alpha therapy
XBIT Ratings Summary
XBIT Quant Ranking